Monique Minnema, PhD, from the University Medical Center, Utrecht, Netherlands, discusses the logistical challenges surrounding CAR T-cell therapy which arise from the treatment of progressive patients with a living cellular product.Dr Monique Minnema then goes onto to describe a specific example of when this presented a problem and the importance of timing and logistical management with CAR T-cell therapy. Recorded at the 1st European CAR T-Cell meeting in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA).